Chronic Pain Market Size, Share and Global Trends - 2025

Upcoming

2023

Chronic Pain Market

by Product (Drug, Devices), by Application (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer Pain, Migraine, Fibromyalgia, Others) and by End User (Hospitals, Clinics, Research Organization): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals	Report Code: A05139	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Chronic Pain Market

Request Now !

Chronic pain is caused by pain signals in nervous system that can persist for months, even for a year. Pain that lasts at least 12 weeks is usually considered to be chronic pain. It is commonly caused due to cancer, arthritis, and neurogenic pain, however, some people suffer from chronic pain in the absence of any past injury commonly caused as psychogenic pain. Some of the commonly used medications for chronic pain are nonsteroidal anti-inflammatory drugs, opioid pain relievers, and adjuvant analgesics. However, patients as well as healthcare professionals are proactively exploring alternative pain relief therapies, owing to surge in awareness about potential implications of prolonged use of pain treatment drugs such as risk of addiction and side effects.

Upsurge in geriatric population, increase in government funding for treatment, and rise in prevalence of chronic health conditions are the notable factors that drive the market growth. Furthermore, increase in adoption of pain management solutions such as analgesic infusion pumps and non-opioids pain treatment methods has fueled the growth of the market.

Initiatives implemented by the national and international government organizations, globally for incasing awareness and funding for the management of chronic pain play pivotal role in the growth of the market. For instance, the International Association for the Study of Pain launched projects in developing countries in January 2018 to increase pain education and practice in developing countries by providing grants. These grants are intended to improve the scope and availability of essential education of clinicians involved in pain treatment and working in all disciplines to encourage development of innovative approaches. Thus, increase in government funding pertaining to the study on chronic pain treatment is anticipated to boost the growth of the market in the coming years.

The chronic pain market is segmented based on product, application, end user, and region. Depending on product, the market is divided into devices and drugs. The applications covered in the market include cancer pain, postoperative pain, low back pain, orthopedic, neuropathic, fibromyalgia, anesthesia, cough suppression, diarrhea suppression, and de-addiction. On the basis of end user, the market is classified into hospital, clinics, and research organization. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players are seeking approvals for various drugs used in treatment of chronic pain. For instance, in November 2018, Eli Lilly and Company submitted a new drug application to the United States Food and Drugs Administration for lamifiban, for the treatment of migraine with or without aura, stage of migraine, in adults. The key manufacturers operating in the chronic pain treatment industry include Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Medtronic Plc., Boston Scientific Corporation, Novartis AG, Johnson & Johnson, AstraZeneca PLC, Bristol-Myers Squibb Company, and Becton.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current trends and future estimations which assists to identify the prevailing chronic pain market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global chronic pain market is provided.
Region-wise and country-wise chronic pain market conditions are comprehensively analyzed in this report.
Key market players within the chronic pain market are profiled in this report and their strategies are analyzed thoroughly, which helps to understand the competitive outlook of the global chronic pain market.

Chronic Pain Market Report Highlights

Aspects	Details
By Product	Drug Devices
By Application	Neuropathic pain Arthritis pain Chronic back pain Cancer Pain Migraine Fibromyalgia Others
By End User	Hospitals Clinics Research Organization
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Medtronic Plc., Johnson & Johnson, Boston Scientific Corporation, Pfizer Inc., Eli Lilly and Company, Becton, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Abbott Laboratories

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: CHRONIC PAIN MARKET, BY PRODUCT
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Product
- 4.2. Drug
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Devices
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
CHAPTER 5: CHRONIC PAIN MARKET, BY APPLICATION
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Application
- 5.2. Neuropathic Pain
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Arthritis Pain
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Chronic Back Pain
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country
- 5.5. Cancer Pain
  - 5.5.1. Key Market Trends, Growth Factors and Opportunities
  - 5.5.2. Market Size and Forecast, By Region
  - 5.5.3. Market Share Analysis, By Country
- 5.6. Migraine
  - 5.6.1. Key Market Trends, Growth Factors and Opportunities
  - 5.6.2. Market Size and Forecast, By Region
  - 5.6.3. Market Share Analysis, By Country
- 5.7. Fibromyalgia
  - 5.7.1. Key Market Trends, Growth Factors and Opportunities
  - 5.7.2. Market Size and Forecast, By Region
  - 5.7.3. Market Share Analysis, By Country
- 5.8. Others
  - 5.8.1. Key Market Trends, Growth Factors and Opportunities
  - 5.8.2. Market Size and Forecast, By Region
  - 5.8.3. Market Share Analysis, By Country
CHAPTER 6: CHRONIC PAIN MARKET, BY END USER
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By End User
- 6.2. Hospitals
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Clinics
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
- 6.4. Research Organization
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country
CHAPTER 7: CHRONIC PAIN MARKET, BY REGION
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
  - 7.2.1. Key Market Trends and Opportunities
  - 7.2.2. Market Size and Forecast, By Product
  - 7.2.3. Market Size and Forecast, By Application
  - 7.2.4. Market Size and Forecast, By End User
  - 7.2.5. Market Size and Forecast, By Country
  - 7.2.6. U.S. Chronic Pain Market
    - 7.2.6.1. Market Size and Forecast, By Product
    - 7.2.6.2. Market Size and Forecast, By Application
    - 7.2.6.3. Market Size and Forecast, By End User
  - 7.2.7. Canada Chronic Pain Market
    - 7.2.7.1. Market Size and Forecast, By Product
    - 7.2.7.2. Market Size and Forecast, By Application
    - 7.2.7.3. Market Size and Forecast, By End User
  - 7.2.8. Mexico Chronic Pain Market
    - 7.2.8.1. Market Size and Forecast, By Product
    - 7.2.8.2. Market Size and Forecast, By Application
    - 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
  - 7.3.1. Key Market Trends and Opportunities
  - 7.3.2. Market Size and Forecast, By Product
  - 7.3.3. Market Size and Forecast, By Application
  - 7.3.4. Market Size and Forecast, By End User
  - 7.3.5. Market Size and Forecast, By Country
  - 7.3.6. France Chronic Pain Market
    - 7.3.6.1. Market Size and Forecast, By Product
    - 7.3.6.2. Market Size and Forecast, By Application
    - 7.3.6.3. Market Size and Forecast, By End User
  - 7.3.7. Germany Chronic Pain Market
    - 7.3.7.1. Market Size and Forecast, By Product
    - 7.3.7.2. Market Size and Forecast, By Application
    - 7.3.7.3. Market Size and Forecast, By End User
  - 7.3.8. Italy Chronic Pain Market
    - 7.3.8.1. Market Size and Forecast, By Product
    - 7.3.8.2. Market Size and Forecast, By Application
    - 7.3.8.3. Market Size and Forecast, By End User
  - 7.3.9. Spain Chronic Pain Market
    - 7.3.9.1. Market Size and Forecast, By Product
    - 7.3.9.2. Market Size and Forecast, By Application
    - 7.3.9.3. Market Size and Forecast, By End User
  - 7.3.10. UK Chronic Pain Market
    - 7.3.10.1. Market Size and Forecast, By Product
    - 7.3.10.2. Market Size and Forecast, By Application
    - 7.3.10.3. Market Size and Forecast, By End User
  - 7.3.11. Russia Chronic Pain Market
    - 7.3.11.1. Market Size and Forecast, By Product
    - 7.3.11.2. Market Size and Forecast, By Application
    - 7.3.11.3. Market Size and Forecast, By End User
  - 7.3.12. Rest Of Europe Chronic Pain Market
    - 7.3.12.1. Market Size and Forecast, By Product
    - 7.3.12.2. Market Size and Forecast, By Application
    - 7.3.12.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
  - 7.4.1. Key Market Trends and Opportunities
  - 7.4.2. Market Size and Forecast, By Product
  - 7.4.3. Market Size and Forecast, By Application
  - 7.4.4. Market Size and Forecast, By End User
  - 7.4.5. Market Size and Forecast, By Country
  - 7.4.6. China Chronic Pain Market
    - 7.4.6.1. Market Size and Forecast, By Product
    - 7.4.6.2. Market Size and Forecast, By Application
    - 7.4.6.3. Market Size and Forecast, By End User
  - 7.4.7. Japan Chronic Pain Market
    - 7.4.7.1. Market Size and Forecast, By Product
    - 7.4.7.2. Market Size and Forecast, By Application
    - 7.4.7.3. Market Size and Forecast, By End User
  - 7.4.8. India Chronic Pain Market
    - 7.4.8.1. Market Size and Forecast, By Product
    - 7.4.8.2. Market Size and Forecast, By Application
    - 7.4.8.3. Market Size and Forecast, By End User
  - 7.4.9. South Korea Chronic Pain Market
    - 7.4.9.1. Market Size and Forecast, By Product
    - 7.4.9.2. Market Size and Forecast, By Application
    - 7.4.9.3. Market Size and Forecast, By End User
  - 7.4.10. Australia Chronic Pain Market
    - 7.4.10.1. Market Size and Forecast, By Product
    - 7.4.10.2. Market Size and Forecast, By Application
    - 7.4.10.3. Market Size and Forecast, By End User
  - 7.4.11. Thailand Chronic Pain Market
    - 7.4.11.1. Market Size and Forecast, By Product
    - 7.4.11.2. Market Size and Forecast, By Application
    - 7.4.11.3. Market Size and Forecast, By End User
  - 7.4.12. Malaysia Chronic Pain Market
    - 7.4.12.1. Market Size and Forecast, By Product
    - 7.4.12.2. Market Size and Forecast, By Application
    - 7.4.12.3. Market Size and Forecast, By End User
  - 7.4.13. Indonesia Chronic Pain Market
    - 7.4.13.1. Market Size and Forecast, By Product
    - 7.4.13.2. Market Size and Forecast, By Application
    - 7.4.13.3. Market Size and Forecast, By End User
  - 7.4.14. Rest of Asia Pacific Chronic Pain Market
    - 7.4.14.1. Market Size and Forecast, By Product
    - 7.4.14.2. Market Size and Forecast, By Application
    - 7.4.14.3. Market Size and Forecast, By End User
- 7.5. LAMEA
  - 7.5.1. Key Market Trends and Opportunities
  - 7.5.2. Market Size and Forecast, By Product
  - 7.5.3. Market Size and Forecast, By Application
  - 7.5.4. Market Size and Forecast, By End User
  - 7.5.5. Market Size and Forecast, By Country
  - 7.5.6. Brazil Chronic Pain Market
    - 7.5.6.1. Market Size and Forecast, By Product
    - 7.5.6.2. Market Size and Forecast, By Application
    - 7.5.6.3. Market Size and Forecast, By End User
  - 7.5.7. South Africa Chronic Pain Market
    - 7.5.7.1. Market Size and Forecast, By Product
    - 7.5.7.2. Market Size and Forecast, By Application
    - 7.5.7.3. Market Size and Forecast, By End User
  - 7.5.8. Saudi Arabia Chronic Pain Market
    - 7.5.8.1. Market Size and Forecast, By Product
    - 7.5.8.2. Market Size and Forecast, By Application
    - 7.5.8.3. Market Size and Forecast, By End User
  - 7.5.9. UAE Chronic Pain Market
    - 7.5.9.1. Market Size and Forecast, By Product
    - 7.5.9.2. Market Size and Forecast, By Application
    - 7.5.9.3. Market Size and Forecast, By End User
  - 7.5.10. Argentina Chronic Pain Market
    - 7.5.10.1. Market Size and Forecast, By Product
    - 7.5.10.2. Market Size and Forecast, By Application
    - 7.5.10.3. Market Size and Forecast, By End User
  - 7.5.11. Rest of LAMEA Chronic Pain Market
    - 7.5.11.1. Market Size and Forecast, By Product
    - 7.5.11.2. Market Size and Forecast, By Application
    - 7.5.11.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning,2022
CHAPTER 9: COMPANY PROFILES
- 9.1. Eli Lilly And Company
  - 9.1.1. Company Overview
  - 9.1.2. Key Executives
  - 9.1.3. Company Snapshot
  - 9.1.4. Operating Business Segments
  - 9.1.5. Product Portfolio
  - 9.1.6. Business Performance
  - 9.1.7. Key Strategic Moves and Developments
- 9.2. Pfizer Inc.
  - 9.2.1. Company Overview
  - 9.2.2. Key Executives
  - 9.2.3. Company Snapshot
  - 9.2.4. Operating Business Segments
  - 9.2.5. Product Portfolio
  - 9.2.6. Business Performance
  - 9.2.7. Key Strategic Moves and Developments
- 9.3. Abbott Laboratories
  - 9.3.1. Company Overview
  - 9.3.2. Key Executives
  - 9.3.3. Company Snapshot
  - 9.3.4. Operating Business Segments
  - 9.3.5. Product Portfolio
  - 9.3.6. Business Performance
  - 9.3.7. Key Strategic Moves and Developments
- 9.4. Medtronic Plc.
  - 9.4.1. Company Overview
  - 9.4.2. Key Executives
  - 9.4.3. Company Snapshot
  - 9.4.4. Operating Business Segments
  - 9.4.5. Product Portfolio
  - 9.4.6. Business Performance
  - 9.4.7. Key Strategic Moves and Developments
- 9.5. Boston Scientific Corporation
  - 9.5.1. Company Overview
  - 9.5.2. Key Executives
  - 9.5.3. Company Snapshot
  - 9.5.4. Operating Business Segments
  - 9.5.5. Product Portfolio
  - 9.5.6. Business Performance
  - 9.5.7. Key Strategic Moves and Developments
- 9.6. Novartis AG
  - 9.6.1. Company Overview
  - 9.6.2. Key Executives
  - 9.6.3. Company Snapshot
  - 9.6.4. Operating Business Segments
  - 9.6.5. Product Portfolio
  - 9.6.6. Business Performance
  - 9.6.7. Key Strategic Moves and Developments
- 9.7. Johnson And Johnson
  - 9.7.1. Company Overview
  - 9.7.2. Key Executives
  - 9.7.3. Company Snapshot
  - 9.7.4. Operating Business Segments
  - 9.7.5. Product Portfolio
  - 9.7.6. Business Performance
  - 9.7.7. Key Strategic Moves and Developments
- 9.8. AstraZeneca PLC
  - 9.8.1. Company Overview
  - 9.8.2. Key Executives
  - 9.8.3. Company Snapshot
  - 9.8.4. Operating Business Segments
  - 9.8.5. Product Portfolio
  - 9.8.6. Business Performance
  - 9.8.7. Key Strategic Moves and Developments
- 9.9. Bristol-Myers Squibb Company
  - 9.9.1. Company Overview
  - 9.9.2. Key Executives
  - 9.9.3. Company Snapshot
  - 9.9.4. Operating Business Segments
  - 9.9.5. Product Portfolio
  - 9.9.6. Business Performance
  - 9.9.7. Key Strategic Moves and Developments
- 9.10. Becton
  - 9.10.1. Company Overview
  - 9.10.2. Key Executives
  - 9.10.3. Company Snapshot
  - 9.10.4. Operating Business Segments
  - 9.10.5. Product Portfolio
  - 9.10.6. Business Performance
  - 9.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL CHRONIC PAIN MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 2. GLOBAL CHRONIC PAIN MARKET FOR DRUG, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL CHRONIC PAIN MARKET FOR DEVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL CHRONIC PAIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 5. GLOBAL CHRONIC PAIN MARKET FOR NEUROPATHIC PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL CHRONIC PAIN MARKET FOR ARTHRITIS PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 7. GLOBAL CHRONIC PAIN MARKET FOR CHRONIC BACK PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 8. GLOBAL CHRONIC PAIN MARKET FOR CANCER PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL CHRONIC PAIN MARKET FOR MIGRAINE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL CHRONIC PAIN MARKET FOR FIBROMYALGIA, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL CHRONIC PAIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL CHRONIC PAIN MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 13. GLOBAL CHRONIC PAIN MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL CHRONIC PAIN MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL CHRONIC PAIN MARKET FOR RESEARCH ORGANIZATION, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GLOBAL CHRONIC PAIN MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA CHRONIC PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 21. U.S. CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 22. U.S. CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. U.S. CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 24. CANADA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 25. CANADA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. CANADA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 27. MEXICO CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 28. MEXICO CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. MEXICO CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 30. EUROPE CHRONIC PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 31. EUROPE CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 32. EUROPE CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. EUROPE CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 34. FRANCE CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 35. FRANCE CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 37. GERMANY CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 38. GERMANY CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. GERMANY CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 40. ITALY CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 41. ITALY CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. ITALY CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 43. SPAIN CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 44. SPAIN CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 46. UK CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 47. UK CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. UK CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 49. RUSSIA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 50. RUSSIA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. RUSSIA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 52. REST OF EUROPE CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. REST OF EUROPE CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. REST OF EUROPE CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC CHRONIC PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 56. ASIA-PACIFIC CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 57. ASIA-PACIFIC CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. ASIA-PACIFIC CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 59. CHINA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 60. CHINA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. CHINA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 62. JAPAN CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 63. JAPAN CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. JAPAN CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 65. INDIA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 66. INDIA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. INDIA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. SOUTH KOREA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 71. AUSTRALIA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 72. AUSTRALIA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. AUSTRALIA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 74. THAILAND CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 75. THAILAND CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. THAILAND CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 77. MALAYSIA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. MALAYSIA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. MALAYSIA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 80. INDONESIA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 81. INDONESIA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 82. INDONESIA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 83. REST OF ASIA PACIFIC CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 84. REST OF ASIA PACIFIC CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. REST OF ASIA PACIFIC CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 86. LAMEA CHRONIC PAIN, BY REGION, 2022-2032 ($MILLION)
TABLE 87. LAMEA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 88. LAMEA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. LAMEA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 90. BRAZIL CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 91. BRAZIL CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. BRAZIL CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 93. SOUTH AFRICA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. SOUTH AFRICA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 95. SOUTH AFRICA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 96. SAUDI ARABIA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 97. SAUDI ARABIA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 98. SAUDI ARABIA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 99. UAE CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 100. UAE CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. UAE CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 102. ARGENTINA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 103. ARGENTINA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 104. ARGENTINA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 105. REST OF LAMEA CHRONIC PAIN, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 106. REST OF LAMEA CHRONIC PAIN, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 107. REST OF LAMEA CHRONIC PAIN, BY END USER, 2022-2032 ($MILLION)
TABLE 108. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 109. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 110. ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 111. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 112. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113. PFIZER INC.: KEY EXECUTIVES
TABLE 114. PFIZER INC.: COMPANY SNAPSHOT
TABLE 115. PFIZER INC.: OPERATING SEGMENTS
TABLE 116. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 117. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 119. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 120. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 121. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 122. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123. MEDTRONIC PLC.: KEY EXECUTIVES
TABLE 124. MEDTRONIC PLC.: COMPANY SNAPSHOT
TABLE 125. MEDTRONIC PLC.: OPERATING SEGMENTS
TABLE 126. MEDTRONIC PLC.: PRODUCT PORTFOLIO
TABLE 127. MEDTRONIC PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 128. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
TABLE 129. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 130. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 131. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 132. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 133. NOVARTIS AG: KEY EXECUTIVES
TABLE 134. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 135. NOVARTIS AG: OPERATING SEGMENTS
TABLE 136. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 137. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 138. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 139. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 140. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 141. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 142. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 144. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 145. ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 146. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 147. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 148. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 149. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 150. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 151. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 152. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 153. BECTON: KEY EXECUTIVES
TABLE 154. BECTON: COMPANY SNAPSHOT
TABLE 155. BECTON: OPERATING SEGMENTS
TABLE 156. BECTON: PRODUCT PORTFOLIO
TABLE 157. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL CHRONIC PAIN MARKET SEGMENTATION
FIGURE 2. GLOBAL CHRONIC PAIN MARKET
FIGURE 3. SEGMENTATION CHRONIC PAIN MARKET
FIGURE 4. TOP INVESTMENT POCKET IN CHRONIC PAIN MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHRONIC PAIN MARKET
FIGURE 11. CHRONIC PAIN MARKET SEGMENTATION, BY BY PRODUCT
FIGURE 12. CHRONIC PAIN MARKET FOR DRUG, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. CHRONIC PAIN MARKET FOR DEVICES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. CHRONIC PAIN MARKET SEGMENTATION, BY BY APPLICATION
FIGURE 15. CHRONIC PAIN MARKET FOR NEUROPATHIC PAIN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. CHRONIC PAIN MARKET FOR ARTHRITIS PAIN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 17. CHRONIC PAIN MARKET FOR CHRONIC BACK PAIN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 18. CHRONIC PAIN MARKET FOR CANCER PAIN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. CHRONIC PAIN MARKET FOR MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 20. CHRONIC PAIN MARKET FOR FIBROMYALGIA, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 21. CHRONIC PAIN MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 22. CHRONIC PAIN MARKET SEGMENTATION, BY BY END USER
FIGURE 23. CHRONIC PAIN MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 24. CHRONIC PAIN MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 25. CHRONIC PAIN MARKET FOR RESEARCH ORGANIZATION, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 30. COMPETITIVE DASHBOARD
FIGURE 31. COMPETITIVE HEATMAP: CHRONIC PAIN MARKET
FIGURE 32. Top player positioning, 2022
FIGURE 33. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 34. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 35. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 36. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 37. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 38. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 39. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 41. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 42. MEDTRONIC PLC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 43. MEDTRONIC PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 44. MEDTRONIC PLC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 45. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 46. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 47. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 48. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 50. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 51. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 52. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 53. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 54. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 56. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 57. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 59. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 60. BECTON: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. BECTON: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 62. BECTON: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Chronic Pain Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Chronic Pain Market

Chronic Pain Market

by Product (Drug, Devices), by Application (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer Pain, Migraine, Fibromyalgia, Others) and by End User (Hospitals, Clinics, Research Organization): Global Opportunity Analysis and Industry Forecast, 2023-2032

COVID-19

KEY BENEFITS FOR STAKEHOLDERS

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: CHRONIC PAIN MARKET, BY PRODUCT

4.1. Market Overview

4.1.1 Market Size and Forecast, By Product

4.2. Drug

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Devices

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

CHAPTER 5: CHRONIC PAIN MARKET, BY APPLICATION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Application

5.2. Neuropathic Pain

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Arthritis Pain

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

5.4. Chronic Back Pain

5.4.1. Key Market Trends, Growth Factors and Opportunities

5.4.2. Market Size and Forecast, By Region

5.4.3. Market Share Analysis, By Country

5.5. Cancer Pain

5.5.1. Key Market Trends, Growth Factors and Opportunities

5.5.2. Market Size and Forecast, By Region

5.5.3. Market Share Analysis, By Country

5.6. Migraine

5.6.1. Key Market Trends, Growth Factors and Opportunities

5.6.2. Market Size and Forecast, By Region

5.6.3. Market Share Analysis, By Country

5.7. Fibromyalgia

5.7.1. Key Market Trends, Growth Factors and Opportunities

5.7.2. Market Size and Forecast, By Region

5.7.3. Market Share Analysis, By Country

5.8. Others

5.8.1. Key Market Trends, Growth Factors and Opportunities

5.8.2. Market Size and Forecast, By Region

5.8.3. Market Share Analysis, By Country

CHAPTER 6: CHRONIC PAIN MARKET, BY END USER

6.1. Market Overview

6.1.1 Market Size and Forecast, By End User

Chronic Pain Market
Global Opportunity Analysis and Industry Forecast, 2023-2032